Support Cancer Research Funding: Sponsor a Scientist
Sponsor a Scientist
Funding OCRA’s scientific research initiatives is one of the most powerful ways to support our life-saving work.

Contribute to Groundbreaking Research
Our Partners in Science program allows you to directly contribute to groundbreaking research aimed at preventing ovarian and related gynecologic cancers, developing better, more effective treatments, and ultimately finding a cure.
Program Details
The OCRA Partners in Science program offers donors a unique opportunity to sponsor specific scientists based on personalized criteria, fostering a meaningful connection between donors and researchers. The minimum contribution is $20,000.
-
Donors choose scientists to sponsor based on factors like geographic location, institution, or area of study. Sponsored researchers are selected from projects reviewed and approved annually by OCRA’s Scientific Advisory Committee (SAC).
-
Donors can review detailed grant information, including project summaries, abstracts, or full proposals. There’s ongoing communication between donors and researchers, with possibilities for personalized lab tours. Donors also receive regular updates on research progress, final summaries, annual reports, and publications resulting from the research.
-
Donors can sponsor multiple investigators depending on the contribution amount or co-sponsor a research project with others.
-
The program is open to individual donors, private family foundations, organizations, community events, and groups of friends or relatives supporting research on behalf of a loved one. OCRA staff provide guidance throughout the selection process, ensuring a meaningful and personal experience.
-
Donors’ support is acknowledged on the OCRA website, and grants can be named in honor or in memory of a loved one.
Partners in Science Donors
Become a Partner in Science
To learn more about becoming an OCRA Partner in Science, please contact Jon Zeidman, Chief Development Officer, at jzeidman@ocrahope.org or 212-268-1002.
Related Topics

FDA Gives Its First-Ever Approval of Treatment for KRAS-Mutated Recurrent Low-Grade Serous Ovarian Cancer
The Food and Drug Administration has granted accelerated approval to Avmapki Fakzynja Co-pack (avutometinib capsules; defactinib tablets), made by Verastem Oncology, making it the first FDA-approved treatment for patients with … Continued

Global Research Push Resonates Across Airwaves
News of the newly launched Global Ovarian Cancer Research Consortium — and its inaugural AI Accelerator Grant — is spreading quickly, with media outlets across the country taking notice. The … Continued

New Global Ovarian Cancer Research Consortium Joins Forces with Microsoft’s AI for Good Lab to Launch First-Of-Its-Kind $1M Global Grant to Improve Survival Rates
Four leading ovarian cancer research charities from four countries are funding a new AI Accelerator Grant in partnership with Microsoft’s AI for Good Lab to supercharge the next cancer research … Continued